TGF-β / Smad Signaling - ROCK
The TGF-β family is generally classified into two sub-families, TGF-β ligands, and bone morphogenic protein (BMP) ligands. In canonical signaling, receptor activation lead to phosphorylation of a group of transcription factors called Smads. TGF-β ligands bind to type II receptors (TGF-β II) which recruit and phosphorylate type I receptor (TGF-β I) on serine/threonine residues. The TGF-β I then recruits and phosphorylates a receptor regulated Smad (R-Smad). The R-Smad binds to the common Smad (Co-Smad) and forms a heterodimeric complex. This complex then translocates into the cell nucleus where it binds with nuclear co-factors to regulate the transcription of various target genes. Dysregulation of TGF-β/Smad signaling pathway is associated with a number of pathological conditions including fibrosis, cancer, immunodeficiency, diabetes and cardiovascular diseases etc.
- B7807 Netarsudil (AR-13324)Target: ROCKSummary: ROCK抑制剂
- B3392 GSK269962ATarget: ROCK|RSK|MSKSummary: ROCK抑制剂
- B1294 SR-3677Target: ROCKSummary: Rho激酶(ROCK-II)抑制剂
- B1293 Y-276329 CitationTarget: ROCKSummary: ROCK选择性抑制剂
- A5734 Fasudil (HA-1077) HCl1 Citation中文名: 盐酸法舒地尔Target: ROCKSummary: 蛋白激酶抑制剂
- A5611 GSK429286ATarget: ROCKSummary: 选择性ROCK1/ROCK2抑制剂
- A5506 ThiazovivinTarget: ROCKSummary: ROCK抑制剂
- A3825 SLx-21191 CitationTarget: ROCKSummary: ROCK2抑制剂
- A3771 RKI-1447Target: ROCKSummary: ROCK1/ROCK2抑制剂
- A3478 Hydroxyfasudil中文名: 羟基法舒地尔Target: ROCK|Rho-kinaseSummary: Rho激酶抑制剂和血管扩张剂